Home › Research › Treatments
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN et al.. JAMA, 2003-05-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective To evaluate the effect of estrogen plus progestin on the incidence of dementia and mild cognitive impairment compared with placebo. Results The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years. Overall, 61 women were diagnosed with probable dementia, 40 (66%) in the estrogen plus progestin group compared with 21 (34%) in the placebo group. This increased risk would result in an additional 23 cases of dementia per 10 000 women per year. These findings, coupled with previously reported WHI data, support the conclusion that the risks of estrogen plus progestin outweigh the benefits.
What this study adds
Evidence grade: High
This is a trial of 2,229 participants. In this randomized, placebo-controlled trial within the Women's Health Initiative, 61 postmenopausal women were diagnosed with probable dementia over an average of about 4 years: 40 in the estrogen-plus-progestin group and 21 in the placebo group. Reported effect size: 92.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shumaker, S. A., Legault, C., Rapp, SR., Thal, L., Wallace, R. B., Ockene, J. K., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. https://doi.org/10.1001/jama.289.20.2651
Vancouver
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003. doi:10.1001/jama.289.20.2651. PMID: 12771112.
BibTeX
@article{shumaker2003-12771112,
author = {Shumaker, S. A. and Legault, C. and Rapp, SR. and Thal, L. and Wallace, R. B. and Ockene, J. K. and Hendrix, S. L. and Jones, B. N. and others},
title = {{Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial}},
journal = {JAMA},
year = {2003},
doi = {10.1001/jama.289.20.2651},
pmid = {12771112},
url = {https://doi.org/10.1001/jama.289.20.2651}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To evaluate the effect of estrogen plus progestin on the incidence of dementia and mild cognitive impairment compared with placebo.
- Results The mean (SD) time between the date of randomization into WHI and the last Modified Mini-Mental State Examination (3MSE) for all WHIMS participants was 4.05 (1.19) years.
- Overall, 61 women were diagnosed with probable dementia, 40 (66%) in the estrogen plus progestin group compared with 21 (34%) in the placebo group.
- This increased risk would result in an additional 23 cases of dementia per 10 000 women per year.
- These findings, coupled with previously reported WHI data, support the conclusion that the risks of estrogen plus progestin outweigh the benefits.
Why it matters
In this randomized, placebo-controlled trial within the Women's Health Initiative, 61 postmenopausal women were diagnosed with probable dementia over an average of about 4 years: 40 in the estrogen-plus-progestin group and 21 in the placebo group. The authors estimate this means "an additional 23 cases of dementia per 10 000 women per year", and say that these findings, "coupled with previously reported WHI data", support the conclusion that the risks of estrogen plus progestin outweigh the benefits. The record does not report results for mild cognitive impairment or for estrogen taken alone.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants2,229
- Effect size92.6%
- Evidence strengthHigh
How this study scored 72/100
Published in a top-tier journal. Scored zero for study design because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 69 of the 96 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 3 / 4 | 2,229 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 7 / 7 | Cited 2,179 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 87.2 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 6 / 6 | Cited 134.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 41 other studies in this library |
| Still being cited | 3 / 4 | Cited 179 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author for the WHIMS Investigators holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Wake Forest University: institution h-index 835 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12771112) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 69 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 69 of the 96 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
41 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “menopause-hrt-and-dementia”
7 studies in the library carry the topic tag “menopause-hrt-and-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 7 tagged studies.